




GMP Solutions for Cell & Gene therapies

GMP VECTOR MANUFACTURING

MolMed provides tailor-made services for Cell & Gene therapy projects, meeting Client's needs in terms of development and GMP manufacturing of retroviral and lentiviral vectors and genetically modified T-cells and Stem cells



Up to **200L**
Vector Manufacturing

Our Facilities



DIBIT Facility (Milan)

- ▶ 1.500 SQM (16.000 SQF) areas of which 400 SQM are classified with Grade B/C suites and Grade C/D shared areas, dedicated to testing and production in accordance with the cGMP guidelines
- ▶ Authorized GMP manufacturing facility since 2003 for clinical programs and since 2015 for European commercial ATMP products



OpenZone Facility (Bresso, Milan)

- ▶ 3.300 SQM (35.000 SQF) areas of which 1.500 SQM are classified with Grade B/C suites including BL3 classified containment area and Grade C/D shared areas, built in with flexible design and in accordance with the highest quality standards dedicated to production in accordance with the cGMP guidelines
- ▶ Authorized GMP manufacturing facility for clinical programs and for European commercial ATMP products since 2017

Retroviral and lentiviral vectors

With its long lasting experience and extremely successful track record MolMed is one of the world leaders in GMP production of retroviral and lentiviral vectors

- Packaging plasmids and packaging cell lines for R&D and GMP activities provided by MolMed for Lentiviral vector manufacturing
- 1-2 Step clone selection for retroviral vector manufacturing
- Customization, development, qualification and validation activities carried out by MolMed's top level expertise
- Proprietary processes with scale ranging from 48L in cell factory to 200L in bioreactor for both retroviral and lentiviral vector manufacturing
- MolMed performs more than 100 analytical tests in-house, resulting in containment of material, costs and release timeline
- Vector release by the Qualified Person for ex vivo and in vivo gene therapy and IMPD/IND support

**For information contact our
Business Development:**
+39 02 212771
business.development@molmed.com



GMP Solutions for Cell & Gene therapies